PMN Stock Analysis: Buy, Sell, or Hold?
PMN - ProMIS Neurosciences Inc. Common Shares (ON)
$9.65
-0.50 (-4.93%)
▼
5d:
-7.88%
30d:
-12.83%
90d:
-59.88%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When PMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PMN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PMN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PMN is currently trading at $9.65, which is considered oversold relative to its 30-day fair value range of $10.22 to $11.03.
Technical Outlook: Technically, PMN is showing sideways momentum. The price is currently testing key support at $9.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.26 (+265.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PMN is showing sideways momentum. The price is currently testing key support at $9.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.26 (+265.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.22 -
$11.03
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 265.4% below Wall St target ($35.26)
- CAUTION: Recommendation downgraded due to -7.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$10.22 -
$11.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.91
Resistance Level
$11.37
Current Trend
Sideways
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.79
Wall Street Target
$35.26
(+265.4%)
Share & Embed Analysis
Last updated: June 03, 2026 5:33 PM ET
Data refreshes hourly during market hours. Next update: 6:33 PM
Data refreshes hourly during market hours. Next update: 6:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PMN showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Patrick D Kirwin
BUY
4000 shares
2026-04-22
Eugene Williams
BUY
2000 shares
2026-03-04
Eugene Williams
BUY
1000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
